A raft of rules that affect the medtech industry are paused for the time being while the new Biden administration determines whether the regulations should indeed move forward. Our reporting on Biden’s reg freeze, and the rules it touches, was of most interest to Medtech Insight readers last month.
A memo from the White House on 20 January – Inauguration Day – to the heads of executive departments requested that they “consider” suspending action on any so-called “midnight...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?